Serum 25-hydroxyvitamin D levels and risk of lung cancer and histologic types::a Mendelian randomisation analysis of the HUNT study by Sun, Yi-Qian et al.
                          Sun, Y-Q., Brumpton, B., Bonilla, C., Lewis, S., Burgess, S., Skorpen,
F., Chen, Y., Nilsen, T. I., Romundstad, P., & Mai, X-M. (2018). Serum
25-hydroxyvitamin D levels and risk of lung cancer and histologic
types: a Mendelian randomisation analysis of the HUNT study.
European Respiratory Journal, 51(6).
https://doi.org/10.1183/13993003.00329-2018
Peer reviewed version
Link to published version (if available):
10.1183/13993003.00329-2018
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via ERS at http://erj.ersjournals.com/content/51/6/1800329.article-info . Please refer to any applicable terms of
use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the




Serum 25-hydroxyvitamin D levels and risk of lung cancer and histologic types: a 
Mendelian randomization analysis of the HUNT study 
Yi-Qian Sun1, *, Ben M Brumpton2, 3, 4, Carolina Bonilla4, Sarah J. Lewis4, Stephen Burgess5, 
6, Frank Skorpen1, Yue Chen7, Tom IL Nilsen8, 9, Pål Richard Romundstad8 and Xiao-Mei 
Mai8 
 
1Department of Clinical and Molecular Medicine (IKOM), NTNU, Norwegian University of 
Science and Technology, Trondheim, Norway. 
2K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, 
NTNU, Norwegian University of Science and Technology, Trondheim, Norway. 
3Department of Thoracic Medicine, St. Olavs Hospital, Trondheim University Hospital, 
Trondheim, Norway. 
4MRC Integrative Epidemiology Unit, School of Social and Community Medicine, 
University of Bristol, Bristol, UK. 
5MRC Biostatistics Unit, University of Cambridge, Cambridge, UK. 
6Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, 
University of Cambridge, Cambridge, UK. 
7School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, 
Ottawa, Canada.  
8Department of Public Health and Nursing, NTNU, Norwegian University of Science and 
Technology, Trondheim, Norway.  





“This is an author-submitted, peer-reviewed version of a manuscript that has been accepted 
for publication in the European Respiratory Journal, prior to copy-editing, formatting and 
typesetting. This version of the manuscript may not be duplicated or reproduced without prior 
permission from the copyright owner, the European Respiratory Society. The publisher is not 
responsible or liable for any errors or omissions in this version of the manuscript or in any 
version derived from it by any other parties. The final, copy-edited, published article, which 




Yi-Qian Sun, PhD 
Department of Clinical and Molecular Medicine (IKOM), NTNU, Norwegian University of 
Science and Technology, Trondheim, Norway 








histologic types, lung cancer, Mendelian randomization, serum 25-hydroxyvitamin D 





For Twitter (≤120 characters): 
Mendelian randomization study did not suggest causal association between serum 25-






We aimed to investigate potential causal associations between serum 25-hydroxyvitamin D 
[25(OH)D] levels and incidence of lung cancer overall and histologic types. 
We performed a Mendelian randomization (MR) analysis using a prospective cohort study in 
Norway, including 54580 individuals and 676 incident lung cancer cases. A 25(OH)D allele 
score was generated based on vitamin D-increasing alleles of rs2282679, rs12785878 and 
rs10741657. Hazard ratios (HRs) with 95% confidence intervals (CIs) for incidence of lung 
cancer and histologic types were estimated in relation to the allele score. Inverse-variance 
weighted method using summarized data of individual single-nucleotide polymorphisms was 
applied to calculate the MR estimates.  
The allele score accounted for 3.4% of the variation in serum 25(OH)D levels. There was no 
association between the allele score and lung cancer incidence overall, with HR being 0.99 
(95% CI 0.93 to 1.06) per allele score. A 25 nmol/L increase in genetically determined 
25(OH)D level was not associated with the incidence of lung cancer overall (MR estimate 
HR 0.96, 95% CI 0.54 to 1.69) or any histologic type.  
MR analysis did not suggest causal association between 25(OH)D levels and risk of lung 






Vitamin D has been suggested to have a number of anti-carcinogenic potentials, such as 
stimulating differentiation, inducing apoptosis, and inhibiting invasion and metastasis [1, 2]. 
Epidemiological studies of the associations between circulating vitamin D and various 
cancers have shown inconsistent results [3, 4]. Lung cancer has been the most common 
cancer type for several decades worldwide, and it is also the most deadly cancer [5]. The 
main histologic types of lung cancer are small cell lung cancer (SCLC), adenocarcinoma and 
squamous cell carcinoma [6]. Adenocarcinoma is the most common histologic type of lung 
cancer in many countries [7]. Unlike SCLC and squamous cell carcinoma, the association 
between smoking and adenocarcinoma is much weaker [8]. Thus, identifying other risk 
factors than tobacco smoking is necessary for further prevention of lung cancer overall and 
certain histologic types. 
Two meta-analyses of observational cohort studies suggested an inverse association 
between serum vitamin D and risk of lung cancer overall [9, 10]. However, conventional 
observational epidemiological studies have limited capability to identify causal associations 
due to potential bias from confounding and reverse causation [11]. Although well-designed 
prospective cohort studies can reduce the possibility of reverse causation, residual and 
unmeasured confounding is inevitable in observational studies. Mendelian randomization 
(MR) studies, however, have been suggested to be able to overcome these limitations and to 
help make causal inferences of modifiable risk factors on health-related outcomes, provided 
that the crucial assumptions are satisfied [11, 12].  
Therefore, we performed a MR study using three single-nucleotide polymorphisms (SNPs) 
as instrumental variables for serum 25-hydroxyvitamin D [25(OH)D], the primary circulating 
form of vitamin D, to explore potential causal associations of serum 25(OH)D levels with 
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Material and methods 
Study population and data linkage 
The Nord-Trøndelag Health Study (HUNT) is a large population-based health study in 
Norway consisting of three separate surveys: HUNT1 (1984–1986), HUNT2 (1995–1997) 
and HUNT3 (2006–2008). The current study was based on data from HUNT2, in which 
65227 subjects aged ≥20 years living in the county of Nord-Trøndelag participated (response 
rate 70%). All participants completed a general questionnaire including questions on health, 
lifestyle and socio-economic status. Blood samples were drawn and body weight and height 
were measured at a clinical examination. The HUNT Research Center received updated 
information about deaths of all causes and emigration of the HUNT participants from the 
Norwegian National Registry in which the dates of such events were recorded for all people 
living in Norway.  
Using the unique 11-digit personal identification number of all residents in Norway, the 
data on HUNT2 participants were linked with data from the Cancer Registry of Norway [13]. 
The ICD-10 (Tenth Revision of the International Statistical Classification of Diseases and 
Related Health Problems) topography codes C33-C34 were used to identify incident lung 
cancer cases among the HUNT2 study participants. Histologic types of lung cancer were 
classified according to the International Classification of Diseases of Oncology (ICD-O) [14]. 
The participants in HUNT2 were followed from the date of participation to the date of lung 
cancer diagnosis, death, emigration, or end of follow-up (December 31, 2014), whichever 
occurred first.  
We excluded subjects who reported ever cancer (n=2400) in the HUNT2 questionnaire at 
baseline, lung cancer cases diagnosed before the participation date (n=13) in the HUNT2 
study and subjects who did not have information on genotype (n=8234), leaving 54580 
subjects in the analysis cohort. Moreover, a 10% random sample (n=6613) of the HUNT2 
8 
 
participants was selected as a subcohort for serum 25(OH)D measurement. After further 
excluding individuals without serum and genotype information, 5546 individuals remained in 
the analysis subcohort.  
Measurement and standardization of serum 25(OH)D levels 
Serum 25(OH)D level is widely recognized as the best available proxy measure for body 
vitamin D status [15, 16]. Serum 25(OH)D levels were measured at the HUNT Biobank using 
LIAISON 25-OH Vitamin D TOTAL (DiaSorin, Saluggia, Italy), a fully automated, 
antibody-based, chemiluminescence assay. The detection range of the assay is 10–375 
nmol/L. Because seasonal fluctuations in 25(OH)D levels were expected due to the high-
latitude geographical position of Norway, a cosinor model based on month of blood draw was 
used to calculate season-standardized 25(OH)D level (nmol/L) that represents the annual 
average value of 25(OH)D for each subject [17]. The season-standardized 25(OH)D was 
calculated using the package cosinor (version 1.1) in R (version 3.4.2). 
Genotyping and imputation of SNPs and allele score as instrumental variables 
DNA was isolated from blood samples collected in HUNT2 and stored at the HUNT biobank. 
Genotyping was performed using Illumina HumanCoreExome arrays as described elsewhere 
[18]. Imputation was performed on samples of recent European ancestry using Minimac3 
(v2.0.1, http://genome.sph.umich.edu/wiki/Minimac3) [19] from a merged reference panel 
constructed from the Haplotype Reference Consortium panel (release version 1.1) [20] and a 
local reference panel based on 2201 whole-genome sequenced HUNT participants [21]. In 
total 3 SNPs located in or near genes for vitamin D synthesis and metabolism were selected 
as instrumental variables for serum 25(OH)D based on two widely-cited GWAS studies [22, 
23]: rs2282679 (GC), rs12785878 (NADSYN1/DHCR7), rs10741657 (CYP2R1). Information 
on rs6013897 that was included in Wang et al. [23] and its proxy SNPs was not available in 
the HUNT study, this SNP, however, showed the weakest effect on 25(OH)D level [23, 24]. 
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The effect allele [25(OH)D increasing allele] was coded as 1 and the other allele was coded 
as 0 (rs2282679: T=1; rs12785878: T=1; and rs10741657: A=1). A 25(OH)D allele score, 
that was a sum of the number of effect alleles of rs2282679, rs12785878 and rs10741657, 
was generated to increase the statistical power of the analyses [25]. The R2 values for linkage 
disequilibrium between these 3 SNPs were calculated [26].  
Statistical analyses 
Linear regression was applied to calculate the F-statistic and R2 value between SNPs or the 
allele score and season-standardized 25(OH)D levels. Values of F-statistic greater than 10 
suggest that the SNPs or allele score are valid instrumental variables [11]. Linear regression 
was used to estimate the associations between the allele score and continuous covariates in 
order to test the assumption that the instrumental variables were not associated with potential 
confounders for the association between serum 25(OH)D and lung cancer; logistic regression 
was used in corresponding analyses of binary covariates. To test if there was a causal 
association between serum 25(OH)D and risk of lung cancer, we used Cox proportional 
hazards regression to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) for 
the incidence of lung cancer overall or histologic types in relation to the allele score. Age was 
used as the time scale in the models. The proportional hazards assumption was satisfied for 
all SNPs and the allele score. In analyses estimating the risk of a specific histologic type, all 
other subtypes were censored at the date of diagnosis.  
To calculate Mendelian randomization estimates of serum 25(OH)D on lung cancer risk, 
we generated summarized data of coefficients and standard errors from linear regression of 
individual SNPs on season-standardized 25(OH)D levels in the subcohort (n=5546), as well 
as coefficients [ln(hazard ratio)] and standard errors from Cox regression of individual SNPs 
on risk of lung cancer overall or a histologic type in the cohort (n=54580). Inverse-variance 
weighted (IVW) and median-based methods were used for the summarized data to calculate 
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MR estimates of serum 25(OH)D for lung cancer overall and histologic types [27]. An IVW 
estimate of the causal effect combines the ratio estimates using each genetic variant in a 
fixed-effect meta-analysis model [28]. To test for pleiotropy we used MR-Egger to calculate 
the intercept and 95% CIs [29]. Additionally, we tested for heterogeneity between SNPs 
using I2 and Cochran’s Q statistic. To test the robustness of our findings, we performed a 
two-sample MR as sensitivity analysis using summarized data of SNPs–25(OH)D association 
derived from a previous consortium study (n≈35000) [24].  
Analyses with summarized data of individual SNPs were carried out using the package 
MendelianRandomization (version 0.2.2) in R (version 3.4.2). All other statistical analyses 
were performed with Stata/SE 14.2 (College Station, TX, USA). 
Ethics 
The study was approved by the Norwegian Regional Committees for Medical and Health 
Research Ethics. All participants gave their informed consent on participation in HUNT, 





During a median follow up of 18 years, a total of 676 incident lung cancer cases were 
diagnosed among the 54580 cohort participants. Table 1 shows the distribution of baseline 
characteristics in the cohort (n=54580) and subcohort (n=5546) of the HUNT2 study. In 
general, the distribution of baseline characteristics was similar between the cohort and 
subcohort. Supplementary table 1 presents the characteristics of SNPs included in the 
25(OH)D allele score in the HUNT2 study. There was no evidence of departure from the 
Hardy-Weinberg equilibrium for the 3 SNPs. The allele frequency was in line with that of the 
1000 Genomes Phase 3 data. The R2 values for linkage disequilibrium between the 3 SNPs 
were <0.1.  
F-statistics and R2 values between SNPs/the allele score and season-standardized 
25(OH)D levels are presented in Table 2. The SNP rs2282679 had the highest F-statistic and 
R2 value among the 3 SNPs, showing 4.0 nmol/L increase in 25(OH)D per effect allele. The 
25(OH)D allele score had a F-statistic of 197 and accounted for 3.4% of the variation of 
serum 25(OH)D levels. The associations between the allele score and the potential 
confounders are presented in Supplementary table 2. In general, taking account of multiple 
testing, there were no clear associations observed.  
Table 3 shows that the 25(OH)D allele score was not associated with the incidence of lung 
cancer overall, with HR being 0.99 (95% CI 0.93 to 1.06) per allele score. There was no clear 
association between the allele score and risk of any histologic type of lung cancer. Based on 
MR estimates using either IVW method or weighted median method, there was little evidence 
that genetically determined season-standardized 25(OH)D was associated with risk of lung 
cancer overall or any histologic type (Table 4 and Figure 1). Using the IVW method, the MR 
estimate HR for lung cancer overall was 0.96 (95% CI 0.54 to 1.69) per 25 nmol/L increase 
in the genetically determined 25(OH)D level.  
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As shown in Table 4, I2 and Cochran’s Q statistic showed no evidence for heterogeneity 
between the SNPs (I2 0.00, 95% CI 0.00 to 0.24, P value was 0.87 for lung cancer overall). 
The P value of the intercept by MR-Egger method was 0.79 (intercept -0.03, 95% CIs -0.25 
to 0.19) for lung cancer overall, suggesting no substantial pleiotropic effect of these SNPs 
(Table 5).  
MR estimates of a 10% increase in genetically determined 25(OH)D level with risks of 
lung cancer and histologic types in a two-sample MR are presented in Supplementary tables 
3-4 and Supplementary figure 1 as sensitivity analyses. All estimates in the two-sample MR 






In this MR analysis of a population-based prospective cohort study including 54580 subjects, 
we found no substantial evidence of a causal association of serum 25(OH)D level with the 
incidence of lung cancer overall, SCLC, adenocarcinoma or squamous cell carcinoma.  
Comparison with other studies 
The finding of the current MR study is inconsistent with the conclusion from two meta-
analyses of observational studies [9, 10]. The results of the meta-analyses may be largely 
driven by the inclusion of a large cohort study showing an inverse association between 
25(OH)D levels and incidence of lung cancer [30], whereas others showed no association [9, 
10]. The current study is also inconsistent with results from our own observational study from 
the same cohort showing that lower 25(OH)D levels were associated with a lower risk of 
adenocarcinoma, particularly in obese individuals [31]. The present MR analysis conformed 
to our speculation that residual confounding by adiposity or adiposity related factors could 
have biased the observational results [31].  
Few MR studies have explored the potential causal association between circulating 
vitamin D levels and lung cancer risk. Our findings are consistent with that of the study by 
Dimitrakopoulou et al. who used summarized data of a consortium (TRICL-ILCCO) 
including a large number of lung cancer cases (n=12537) [32]. Having assumed sufficient 
statistical power to detect moderate effects, they found no causal association between 
circulating vitamin D concentration and risk of lung cancer and certain histologic types 
(adenocarcinoma and squamous cell carcinoma) [32]. Although the conclusions are the same, 
our study differs from the study by Dimitrakopoulou et al. in study design. Our study 
investigated the association in a homogeneous population-based prospective cohort study 
with a long follow-up duration, while TRICL-ILCCO mainly consisted of case-control 
14 
 
studies from different geographical areas and ethnicities [33]. Selection bias is more likely in 
case-control studies than in prospective cohort studies, and survivor bias in MR studies has 
recently been discussed as a methodological issue [34]. Nevertheless, we need to note that the 
causal effect estimates in MR studies generally reflect a life-time risk, regardless of the 
follow-up time. 
Strengths and limitations 
The current study is one of the first MR analyses using a long-term prospective population-
based study to investigate the associations of serum 25(OH)D levels with the risk of lung 
cancer and histologic types. Information about diagnosis of lung cancer at the Cancer 
Registry of Norway is nearly complete and reasonably accurate [35]. However, there were 
many cases with unknown subtypes, resulting in limited statistical power in the analyses of 
histologic types. 
Compared with observational studies, MR studies are not vulnerable to reverse causation 
and unmeasured confounding when the assumptions of MR studies are satisfied. We 
performed both one-sample MR in which we have measured serum 25(OH)D levels in a 
reasonably large subcohort and two-sample MR as a sensitivity analysis. Even though two-
sample MR is getting common with the access to MR Base [36], one-sample MR still has its 
advantages, such as testing the important assumptions of MR directly. F-statistics and R2 
values from the regression of SNPs/allele score on 25(OH)D levels indicated sufficient 
strength of the instrumental variables of the exposure in the current study. The variation of 
25(OH)D explained by the 3 SNPs used in the present study was larger than that explained by 
4 SNPs in the study by Vimaleswaran et al (3.4% vs. 1.9%) [24]. We could also investigate 
the associations between SNPs or the allele score with a broad range of measured and 
reported characteristics at baseline. Even though the instruments may still be associated with 
unmeasured confounding, they were not associated with important confounders such as 
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smoking and socio-economic status in HUNT2. The last important assumption in MR is that 
the instrument (SNPs or allele score) should be associated with the outcome of interest (lung 
cancer) only via the exposure (circulating vitamin D levels). We found no violation of this 
essential assumption according to MR-Egger tests, but fewer genetic instruments may have a 
relatively low power to detect horizontal pleiotropy [29].  
This study had several potential limitations. Non-participation in HUNT2 was about 30% 
of the population. As participants in the HUNT studies were shown to be healthier than non-
participants, our findings might differ to some degree from the true situation in the general 
Norwegian population [37]. The applied MR analysis was based on the assumption that the 
exposure-outcome relationship is linear and in dose-response [11]. We were not able to 
investigate the non-linear association in MR due to the lack of methods for binary outcomes 
[38], whereas many of the reported associations between circulating 25(OH)D levels and 
health outcomes were non-linear [31, 39]. The sample size of this study was likely 
insufficient to reveal a weak to moderate effect of vitamin D on lung cancer risk based on the 
wide confidence intervals of the MR estimates, but the sample size of our cohort seemed 
adequate to detect risk factors with large effects on lung cancer, such as smoking 
(Supplementary table 5). Besides, our results were consistent with the null findings of the 
aforementioned MR study that reported a sufficient study power of a case-control design 
[32]. Nevertheless, consortia consisting of data from European population-based prospective 
studies with long follow-up duration are warranted to further investigate the causality of 
vitamin D on lung cancer in MR analysis. MR studies are also called for in Asia and the 
Middle East where populations are reported to have lower vitamin D levels than populations 
from Europe [40]. In addition, results from ongoing large clinical trials [41, 42] are expected 
to clarify the causal association of vitamin D with cancer and other adverse outcomes, 




In summary, Mendelian randomization analysis indicated that serum 25(OH)D levels were 
not causally associated with the risk of lung cancer overall or histologic types in a 





YQS and this work were supported by The Norwegian Cancer Society (project ID 5769155-
2015) and The Research Council of Norway “Gaveforsterkning”. BMB was supported by a 
Research grant (#46055500-10) from The Liaison Committee for education, research and 
innovation in Central Norway. The K.G. Jebsen Center for Genetic Epidemiology is financed 
by Stiftelsen Kristian Gerhard Jebsen, Faculty of Medicine and Health Sciences, Norwegian 
University of Science and Technology (NTNU) and Central Norway Regional Health 
Authority. 
Disclaimer 
The study has used data from the Cancer Registry of Norway. The interpretation and 
reporting of these data are the sole responsibility of the authors, and no endorsement by the 
Cancer Registry of Norway is intended nor should be inferred. 
Acknowledgments 
The Nord-Trøndelag Health Study (HUNT) is a collaboration between the HUNT Research 
Centre (Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science 
and Technology), the Nord-Trøndelag County Council, and the Norwegian Institute of Public 
Health. The authors especially thank the HUNT Research Centre laboratory personnel for the 
measurement of serum 25(OH)D levels.  
Contributors  
YQS, YC and XMM contributed to the study design. XMM contributed to data collection. 
YQS, BMB, CB, SJL, SB and XMM contributed to statistical analyses of MR. YQS 
conducted statistical analyses, interpreted results and wrote the initial draft of the manuscript. 
BMB, CB, SJL, SB, FS, YC, TILN, PRR and XMM participated in the data interpretation 
and helped to write the final draft of the manuscript. 








1. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential 
for anticancer therapeutics. Nat Rev Cancer 2007: 7(9): 684-700. 
2. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D 
in reducing cancer risk and progression. Nat Rev Cancer 2014: 14(5): 342-357. 
3. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, Willett WC. 
Prospective study of predictors of vitamin D status and cancer incidence and mortality in 
men. J Natl Cancer Inst 2006: 98(7): 451-459. 
4. Jacobs ET, Kohler LN, Kunihiro AG, Jurutka PW. Vitamin D and Colorectal, Breast, 
and Prostate Cancers: A Review of the Epidemiological Evidence. J Cancer 2016: 7(3): 
232-240. 
5. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide 
in 2012. [Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx] 
6. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, 
France: IARC Press, 2004. 
7. Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. The International 
Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. J 
Thorac Oncol 2016: 11(10): 1653-1671. 
8. Lee PN, Forey BA, Coombs KJ. Systematic review with meta-analysis of the 
epidemiological evidence in the 1900s relating smoking to lung cancer. BMC Cancer 
2012: 12: 385. 
9. Liu J, Dong Y, Lu C, Wang Y, Peng L, Jiang M, Tang Y, Zhao Q. Meta-analysis of the 
correlation between vitamin D and lung cancer risk and outcomes. Oncotarget 2017: 
8(46): 81040-81051. 
10. Zhang L, Wang S, Che X, Li X. Vitamin D and lung cancer risk: a comprehensive 
review and meta-analysis. Cell Physiol Biochem 2015: 36(1): 299-305. 
11. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian 
randomization: using genes as instruments for making causal inferences in epidemiology. 
Stat Med 2008: 27(8): 1133-1163. 
12. Lawlor DA. Commentary: Two-sample Mendelian randomization: opportunities and 
challenges. International journal of epidemiology 2016: 45(3): 908-915. 
13. Cancer Registry of Norway. [Available from: https://www.kreftregisteret.no/] 
14. International classification of diseases for oncology (ICD-O). 3rd ed. World Health 
Organization, 2013. 
15. Holick MF. Vitamin D deficiency. N Engl J Med 2007: 357(3): 266-281. 
16. Zerwekh JE. Blood biomarkers of vitamin D status. Am J Clin Nutr 2008: 87(4): 1087s-
1091s. 
17. Degerud E, Hoff R, Nygard O, Strand E, Nilsen DW, Nordrehaug JE, Midttun O, Ueland 
PM, de Vogel S, Dierkes J. Cosinor modelling of seasonal variation in 25-
hydroxyvitamin D concentrations in cardiovascular patients in Norway. Eur J Clin Nutr 
2016: 70(4): 517-522. 
18. Ferreira MA, Vonk JM, Baurecht H, Marenholz I, Tian C, Hoffman JD, Helmer Q, 
Tillander A, Ullemar V, van Dongen J, Lu Y, Ruschendorf F, Esparza-Gordillo J, 
Medway CW, Mountjoy E, Burrows K, Hummel O, Grosche S, Brumpton BM, Witte JS, 
Hottenga JJ, Willemsen G, Zheng J, Rodriguez E, Hotze M, Franke A, Revez JA, 
Beesley J, Matheson MC, Dharmage SC, Bain LM, Fritsche LG, Gabrielsen ME, Balliu 
B, Nielsen JB, Zhou W, Hveem K, Langhammer A, Holmen OL, Loset M, Abecasis GR, 
Willer CJ, Arnold A, Homuth G, Schmidt CO, Thompson PJ, Martin NG, Duffy DL, 
Novak N, Schulz H, Karrasch S, Gieger C, Strauch K, Melles RB, Hinds DA, Hubner N, 
20 
 
Weidinger S, Magnusson PKE, Jansen R, Jorgenson E, Lee YA, Boomsma DI, Almqvist 
C, Karlsson R, Koppelman GH, Paternoster L. Shared genetic origin of asthma, hay fever 
and eczema elucidates allergic disease biology. Nat Genet 2017. 
19. Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A, Vrieze SI, Chew EY, Levy 
S, McGue M, Schlessinger D, Stambolian D, Loh PR, Iacono WG, Swaroop A, Scott LJ, 
Cucca F, Kronenberg F, Boehnke M, Abecasis GR, Fuchsberger C. Next-generation 
genotype imputation service and methods. Nat Genet 2016: 48(10): 1284-1287. 
20. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, Kang HM, 
Fuchsberger C, Danecek P, Sharp K, Luo Y, Sidore C, Kwong A, Timpson N, Koskinen 
S, Vrieze S, Scott LJ, Zhang H, Mahajan A, Veldink J, Peters U, Pato C, van Duijn CM, 
Gillies CE, Gandin I, Mezzavilla M, Gilly A, Cocca M, Traglia M, Angius A, Barrett JC, 
Boomsma D, Branham K, Breen G, Brummett CM, Busonero F, Campbell H, Chan A, 
Chen S, Chew E, Collins FS, Corbin LJ, Smith GD, Dedoussis G, Dorr M, Farmaki AE, 
Ferrucci L, Forer L, Fraser RM, Gabriel S, Levy S, Groop L, Harrison T, Hattersley A, 
Holmen OL, Hveem K, Kretzler M, Lee JC, McGue M, Meitinger T, Melzer D, Min JL, 
Mohlke KL, Vincent JB, Nauck M, Nickerson D, Palotie A, Pato M, Pirastu N, McInnis 
M, Richards JB, Sala C, Salomaa V, Schlessinger D, Schoenherr S, Slagboom PE, Small 
K, Spector T, Stambolian D, Tuke M, Tuomilehto J, Van den Berg LH, Van Rheenen W, 
Volker U, Wijmenga C, Toniolo D, Zeggini E, Gasparini P, Sampson MG, Wilson JF, 
Frayling T, de Bakker PI, Swertz MA, McCarroll S, Kooperberg C, Dekker A, Altshuler 
D, Willer C, Iacono W, Ripatti S, Soranzo N, Walter K, Swaroop A, Cucca F, Anderson 
CA, Myers RM, Boehnke M, McCarthy MI, Durbin R. A reference panel of 64,976 
haplotypes for genotype imputation. Nat Genet 2016: 48(10): 1279-1283. 
21. Zhou W, Fritsche LG, Das S, Zhang H, Nielsen JB, Holmen OL, Chen J, Lin M, 
Elvestad MB, Hveem K, Abecasis GR, Kang HM, Willer CJ. Improving power of 
association tests using multiple sets of imputed genotypes from distributed reference 
panels. Genet Epidemiol 2017: 41(8): 744-755. 
22. Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, 
Jacobs EJ, Ascherio A, Helzlsouer K, Jacobs KB, Li Q, Weinstein SJ, Purdue M, 
Virtamo J, Horst R, Wheeler W, Chanock S, Hunter DJ, Hayes RB, Kraft P, Albanes D. 
Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 2010: 
19(13): 2739-2745. 
23. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, Kiel DP, 
Streeten EA, Ohlsson C, Koller DL, Peltonen L, Cooper JD, O'Reilly PF, Houston DK, 
Glazer NL, Vandenput L, Peacock M, Shi J, Rivadeneira F, McCarthy MI, Anneli P, de 
Boer IH, Mangino M, Kato B, Smyth DJ, Booth SL, Jacques PF, Burke GL, Goodarzi M, 
Cheung CL, Wolf M, Rice K, Goltzman D, Hidiroglou N, Ladouceur M, Wareham NJ, 
Hocking LJ, Hart D, Arden NK, Cooper C, Malik S, Fraser WD, Hartikainen AL, Zhai 
G, Macdonald HM, Forouhi NG, Loos RJ, Reid DM, Hakim A, Dennison E, Liu Y, 
Power C, Stevens HE, Jaana L, Vasan RS, Soranzo N, Bojunga J, Psaty BM, Lorentzon 
M, Foroud T, Harris TB, Hofman A, Jansson JO, Cauley JA, Uitterlinden AG, Gibson Q, 
Jarvelin MR, Karasik D, Siscovick DS, Econs MJ, Kritchevsky SB, Florez JC, Todd JA, 
Dupuis J, Hypponen E, Spector TD. Common genetic determinants of vitamin D 
insufficiency: a genome-wide association study. Lancet 2010: 376(9736): 180-188. 
24. Vimaleswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT, Cooper JD, Dastani 
Z, Li R, Houston DK, Wood AR, Michaelsson K, Vandenput L, Zgaga L, Yerges-
Armstrong LM, McCarthy MI, Dupuis J, Kaakinen M, Kleber ME, Jameson K, Arden N, 
Raitakari O, Viikari J, Lohman KK, Ferrucci L, Melhus H, Ingelsson E, Byberg L, Lind 
L, Lorentzon M, Salomaa V, Campbell H, Dunlop M, Mitchell BD, Herzig KH, Pouta A, 
Hartikainen AL, Streeten EA, Theodoratou E, Jula A, Wareham NJ, Ohlsson C, Frayling 
21 
 
TM, Kritchevsky SB, Spector TD, Richards JB, Lehtimaki T, Ouwehand WH, Kraft P, 
Cooper C, Marz W, Power C, Loos RJ, Wang TJ, Jarvelin MR, Whittaker JC, Hingorani 
AD, Hypponen E. Causal relationship between obesity and vitamin D status: bi-
directional Mendelian randomization analysis of multiple cohorts. PLoS Med 2013: 
10(2): e1001383. 
25. Burgess S, Thompson SG. Use of allele scores as instrumental variables for Mendelian 
randomization. International journal of epidemiology 2013: 42(4): 1134-1144. 
26. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI. SNAP: 
a web-based tool for identification and annotation of proxy SNPs using HapMap. 
Bioinformatics 2008: 24(24): 2938-2939. 
27. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing 
Mendelian randomization analyses using summarized data. International journal of 
epidemiology 2017. 
28. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with 
multiple genetic variants using summarized data. Genet Epidemiol 2013: 37(7): 658-665. 
29. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid 
instruments: effect estimation and bias detection through Egger regression. International 
journal of epidemiology 2015: 44(2): 512-525. 
30. Afzal S, Bojesen SE, Nordestgaard BG. Low plasma 25-hydroxyvitamin D and risk of 
tobacco-related cancer. Clin Chem 2013: 59(5): 771-780. 
31. Sun YQ, Langhammer A, Wu C, Skorpen F, Chen Y, Nilsen TIL, Romundstad PR, Mai 
XM. Associations of serum 25-hydroxyvitamin D level with incidence of lung cancer 
and histologic types in Norwegian adults: a case-cohort analysis of the HUNT study. Eur 
J Epidemiol 2017. 
32. Dimitrakopoulou VI, Tsilidis KK, Haycock PC, Dimou NL, Al-Dabhani K, Martin RM, 
Lewis SJ, Gunter MJ, Mondul A, Shui IM, Theodoratou E, Nimptsch K, Lindstrom S, 
Albanes D, Kuhn T, Key TJ, Travis RC, Vimaleswaran KS, Kraft P, Pierce BL, 
Schildkraut JM. Circulating vitamin D concentration and risk of seven cancers: 
Mendelian randomisation study. BMJ (Clinical research ed) 2017: 359: j4761. 
33. The International Lung Cancer Consortium (ILCCO). [Available from: 
http://ilcco.iarc.fr/] 
34. Vansteelandt S, Dukes O, Martinussen T. Survivor bias in Mendelian randomization 
analysis. Biostatistics 2017. 
35. Larsen IK, Smastuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, Moller B. 
Data quality at the Cancer Registry of Norway: an overview of comparability, 
completeness, validity and timeliness. Eur J Cancer 2009: 45(7): 1218-1231. 
36. Hemani G, Zheng J, Wade KH, Laurin C, Elsworth B, Burgess S, Bowden J, Langdon R, 
Tan V, Yarmolinsky J, Shihab HA, Timpson N, Evans DM, Relton C, Martin RM, Smith 
GD, Gaunt TR, Haycock PC, Collaboration TM-B. MR-Base: a platform for systematic 
causal inference across the phenome using billions of genetic associations. bioRxiv beta, 
the preprint server for biology. [cited 2017; Available from: 
https://www.biorxiv.org/content/early/2016/12/16/078972] 
37. Langhammer A, Krokstad S, Romundstad P, Heggland J, Holmen J. The HUNT study: 
participation is associated with survival and depends on socioeconomic status, diseases 
and symptoms. BMC Med Res Methodol 2012: 12: 143. 
38. Staley JR, Burgess S. Semiparametric methods for estimation of a nonlinear exposure-
outcome relationship using instrumental variables with application to Mendelian 
randomization. Genet Epidemiol 2017: 41(4): 341-352. 
22 
 
39. Sun YQ, Langhammer A, Skorpen F, Chen Y, Mai XM. Serum 25-hydroxyvitamin D 
level, chronic diseases and all-cause mortality in a population-based prospective cohort: 
the HUNT Study, Norway. BMJ Open 2017: 7(6): e017256. 
40. van Schoor NM, Lips P. Worldwide vitamin D status. Best Pract Res Clin Endocrinol 
Metab 2011: 25(4): 671-680. 
41. Kupferschmidt K. Uncertain verdict as vitamin D goes on trial. Science 2012: 337(6101): 
1476-1478. 






Table 1. Distribution of baseline characteristics in the cohort and subcohort of the HUNT2 study, 1995–1997 
 Cohort Subcohort*  
Number of subjects 54580 5546 
Age (years) 49.2±16.6 49.1±16.6 
Season-standardized 25(OH)D level (nmol/L) - 48.3±17.1 
Lung cancer cases 676 77 
Sex, % (women/men) 52.7/47.3 52.8/47.2 
Smoking, % (never/ever/unknown) 42.3/55.8/1.9 42.5/55.4/2.1 
Family history of cancer, % (no/yes) 74.5/25.5 74.1/25.9 
Education (years), % (<10/≥10/unknown) 33.6/61.8/4.6 32.9/62.5/4.6 
Economic difficulties, % (no/yes/unknown) 49.8/21.8/28.3 51.0/21.1/27.9 
Body mass index (BMI, kg/m2), % (<25/≥25/unknown) 39.8/59.4/0.7 40.6/58.8/0.6 
Physical activity, % (inactive/active/unknown)  21.4/48.8/29.9 21.1/49.0/29.8 
Alcohol consumption (times/month), % (never/≥1/unknown) 33.6/58.0/8.4 32.9/59.0/8.1 
Chronic bronchitis, % (no/yes/unknown) 94.6/3.4/2.0 95.0/3.4/1.7 
25(OH)D: 25-hydroxyvitamin D; HUNT2: The Nord-Trøndelag Health Study Survey 2 
Data are given as percentage of subjects or mean ± standard deviation 




Table 2. Coefficient, F-statistic and R2 value of linear regression between SNP/allele score and season-standardized 25(OH)D level (nmol/L) in 
subcohort of the HUNT2 study (n=5546) 
SNP Coefficient* 95% CI P value F-statistic R2 
rs2282679 4.00 (3.30 to 4.71) 1.63×10-28 124 0.022 
rs12785878 1.92 (1.26 to 2.59) 1.36×10-08 32 0.006 
rs10741657 2.48 (1.84 to 3.13) 6.98×10-14 56 0.010 
Allele score† 2.74 (2.36 to 3.12) 5.15×10-44 197 0.034 
25(OH)D: 25-hydroxyvitamin D; CI: confidence interval; HUNT2: The Nord-Trøndelag Health Study Survey 2; SNP: Single-Nucleotide 
Polymorphism 
*Coefficient: change of season-standardized 25(OH)D (nmol/L) per effect allele or per allele score 




Table 3. The associations between the 25(OH)D allele score and risk of lung cancer overall and histologic types in the HUNT2 study (n=54580) 
 Number of cases 
Rate (100000 
PY*) 
HR† 95% CI P value 
Lung cancer overall 676 73.8 0.99 (0.93 to 1.06) 0.83 
  SCLC 90 9.8 0.92 (0.77 to 1.10) 0.35 
  Adenocarcinoma 189 20.6 0.92 (0.82 to 1.04) 0.20 
  Squamous cell carcinoma 141 15.4 0.98 (0.85 to 1.14) 0.82 
  Other/unknown subtypes 256# 27.9 1.08 (0.97 to 1.21) 0.14 
25(OH)D: 25-hydroxyvitamin D; CI: confidence interval; HR: hazard ratio; HUNT2: The Nord-Trøndelag Health Study Survey 2; PY: person-
years; SCLC: small cell lung cancer 
*Time at risk for outcomes: 916480 person-years 
†Per vitamin D-increasing allele score 




Table 4. Mendelian randomization estimates of the associations between a 25 nmol/L increase in genetically determined season-standardized 
25(OH)D and risk of lung cancer overall and histologic types in the HUNT2 study (n=54580) 
Outcome 
IVW method Weighted median method 




I2 (95% CI) 
P value of 
Q statistic 
MR estimate HR 
(95% CI) 
P value 
Lung cancer overall 0.96 (0.54 to 1.69) 0.88 0.00 (0.00 to 0.24) 0.87 1.00 (0.54 to 1.85) 0.99 
  SCLC 0.58 (0.12 to 2.69) 0.48 0.45 (0.00 to 0.84) 0.16 0.82 (0.14 to 4.76) 0.82 
  Adenocarcinoma 0.54 (0.18 to 1.57) 0.26 0.00 (0.00 to 0.62) 0.76 0.61 (0.19 to 1.95) 0.41 
  Squamous cell carcinoma 0.64 (0.19 to 2.17) 0.47 0.08 (0.00 to 0.90) 0.34 0.64 (0.17 to 2.44) 0.52 
  Other/unknown subtypes 2.22 (0.86 to 5.75) 0.10 0.00 (0.00 to 0.72) 0.69 2.69 (0.94 to 7.71) 0.07 
25(OH)D: 25-hydroxyvitamin D; CI: confidence interval; HR: hazard ratio; IVW: inverse-variance weighted; MR: Mendelian randomization; 





Table 5. MR-Egger pleiotropy test of associations between a 25 nmol/L increase in genetically determined season-standardized 25(OH)D and 
risk of lung cancer overall and histologic types in the HUNT2 study (n=54580) 
Outcome 
MR-Egger method 
Intercept (95% CI) P value 
Lung cancer overall -0.03 (-0.25 to 0.19) 0.79 
  SCLC 
 
-0.27 (-1.27 to 0.72) 0.59 
  Adenocarcinoma 
 
-0.14 (-0.55 to 0.27) 0.50 
  Squamous cell carcinoma 
 
0.36 (-0.12 to 0.84) 0.14 
  Other/unknown subtypes 
 
-0.09 (-0.45 to 0.28) 0.64 
25(OH)D: 25-hydroxyvitamin D; CI: confidence interval; MR: Mendelian randomization; SCLC: small cell lung cancer 
 
 
 
